Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31287813.
- Also identified by DOI 10.1371/journal.pmed.1002851 and PMC identifier 6615592.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
Medical subject headings
- Antitubercular Agents
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Drug Development
- Research Design
- Tuberculosis
- Workflow